Drug Efficacy Testing Using Pancreatic Tumor Xenografts

Robust preclinical evaluation of therapeutic agents in pancreatic ductal adenocarcinoma (PDAC) requires models that faithfully imitate patient tumors, including their desmoplastic stroma, hypoxic microenvironments, and immune infiltration. Altogen Labs’ orthotopic PDAC xenografts serve as gold standards for assessing drug efficacy, resistance mechanisms, and biomarker responses.

In a representative study, orthotopic PANC-1 xenograft–bearing mice were randomized to receive a novel dual PI3K/mTOR inhibitor (PI3K/mTORi-14) at 30 mg/kg daily via oral gavage or vehicle control. Baseline tumor volumes measured by high-frequency ultrasound averaged 150 mm³. After three weeks, PI3K/mTORi-14–treated tumors regressed by 65% relative to baseline, while vehicle tumors grew by 200%. Immunohistochemistry (IHC) on tumor sections demonstrated a 75% reduction in pAKT and pS6 staining, indicating effective pathway inhibition. Ki-67 proliferative index decreased by 80%, and TUNEL assays revealed a 3-fold increase in apoptotic cells compared to controls.

To evaluate stromal modulation, Masson’s trichrome staining of treated tumors showed a 40% decrease in collagen I deposition, suggesting that PI3K/mTOR inhibition disrupts pancreatic stellate cell activation. In parallel, intratumoral delivery of siRNA targeting SPARC (secreted protein acidic and rich in cysteine), a matricellular protein associated with desmoplasia, was achieved using Altogen’s Pancreas In Vivo siRNA Kit at 1 mg/kg dose. Mice receiving both PI3K/mTORi-14 and SPARC siRNA exhibited an 85% tumor reduction and further decreased stromal fibrosis, as measured by digital image analysis of IHC.

Altogen Labs also integrates pharmacokinetic (PK) and pharmacodynamic (PD) studies under GLP compliance. Plasma and tumor drug concentrations were quantified via LC-MS/MS, revealing peak tumor concentrations at 4 hours post-dose (C_max = 2.5 µg/g tissue) with a half-life of 8 hours. Biomarker modulation, assessed by western blot analysis of tumor lysates, confirmed sustained target engagement up to 24 hours. Serum amylase and lipase levels were monitored to detect off-target pancreatic enzyme release; values remained within normal limits, indicating negligible ductal toxicity.

For combination therapy assessments, orthotopic MIA PaCa-2 xenograft models received gemcitabine (100 mg/kg twice weekly) plus targeted nanoparticle-delivered siRNA against BCL2 (delivered 48 hours before chemotherapy). Combination treatment led to 75% tumor regression, whereas gemcitabine alone achieved only 30% reduction. Mechanistically, western blotting of tumor lysates demonstrated near-complete suppression of BCL2 and increased cleaved caspase-3, indicating enhanced apoptosis.

By providing these comprehensive orthotopic xenograft services—encompassing tumor implantation, therapeutic administration, biomarker analysis, and pharmacology—Altogen Labs enables researchers to obtain clinically translatable efficacy and safety data for novel agents in pancreatic cancer.